Trulicity Takes Hit From Payer Mix, But Lilly Emerges From Q3 Ahead
COVID-19 Antibody Bamlanivimab Fails In Sicker Patients
US pricing for Trulicity due to payer mix fluctuations dragged down solid volume growth. Lilly hopes revenue from COVID-19 therapies will help it hit annual guidance, but bamlanivimab failed to benefit hospitalized patients.
